KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (Diluted Average) (2019 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $134.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 5.51% year-over-year to $134.7 million, compared with a TTM value of $134.7 million through Dec 2025, up 5.51%, and an annual FY2025 reading of $134.7 million, up 5.51% over the prior year.
  • Shares Outstanding (Diluted Average) was $134.7 million for Q4 2025 at Alnylam Pharmaceuticals, roughly flat from $134.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $134.7 million in Q4 2025 and bottomed at $117.1 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $124.6 million, with a median of $124.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) grew 1.42% in 2024, then increased 5.51% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $118.5 million in 2021, then rose by 2.73% to $121.7 million in 2022, then rose by 2.64% to $124.9 million in 2023, then grew by 2.2% to $127.7 million in 2024, then increased by 5.51% to $134.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for ALNY at $134.7 million in Q4 2025, $134.1 million in Q3 2025, and $130.6 million in Q2 2025.